Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Rare Earth Elements: The Workhorse of The Tech Revolution]( [Read this free investor report to reveal who could benefit in 2024.]( --------------------------------------------------------------- January 25, 2024 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- [Viridian Therapeutics, Inc.]( Ticker: [VRDN]( Recent Price: $19.74 Average Analyst Price Target: $39.25 (98.83%) Market Cap: $1.04B Role Transaction Description No. of Shares Amount Date Director, >10% Owner, Others Informative Buy Non Open Market Buy 476,190 $9,999,990 2 Days Ago Recent Analyst Action: Laura Chico, analyst at Wedbush, reiterates coverage on [Viridian Therapeutics, Inc. (VRDN)]( in the Healthcare sector with a Buy rating and a price target of $39 (3 days ago). Here are 3rd party ratings for [VRDN](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 37% (94 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Elon Musk's "Project Dojo" is a Game-Changer]( Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation. [Click here for its name and ticker symbol (MUST ACT BEFORE MARCH 15).]( --------------------------------------------------------------- [KalVista Pharmaceuticals, Inc.]( Ticker: [KALV]( Recent Price: $12.61 Average Analyst Price Target: $21.00 (66.53%) Market Cap: $435.79M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 99,129 $1,241,685 2 Days Ago Recent Analyst Action: Andrew Fein, analyst at H.C. Wainwright, reiterates coverage on [KalVista Pharmaceuticals, Inc. (KALV)]( in the Healthcare sector with a Buy rating and a price target of $16 (1 month ago). Here are 3rd party ratings for [KALV](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 36% (90 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Texas Capital Bancshares, Inc.]( Ticker: [TCBI]( Recent Price: $63.49 Average Analyst Price Target: $67.40 (6.16%) Market Cap: $3.05B Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 12,000 $227,260 2 Days Ago Recent Analyst Action: Brock Vandervliet, analyst at UBS, reiterates coverage on [Texas Capital Bancshares, Inc. (TCBI)]( in the Financial Services sector with a Sell rating and a price target of $57 (2 days ago). Here are 3rd party ratings for [TCBI](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 41% (102 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Gold Is Headed Above $3,000 per Ounce (Here's How to Play It?]( so many strange events happening across the economy (the longest bear market for bonds since the Civil War... unprecedented bank closures... and soaring prices), it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – WITHOUT ever touching an ETF, mining stock, or even bullion. [Get the full details here.]( --------------------------------------------------------------- [Tilly's, Inc.]( Ticker: [TLYS]( Recent Price: $7.60 Average Analyst Price Target: $8.63 (13.49%) Market Cap: $227.80M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 29,500 $222,325 2 Days Ago Recent Analyst Action: Jeff Van, analyst at B.Riley Financial, reiterates coverage on [Tilly's, Inc. (TLYS)]( in the Consumer Cyclical sector with a Hold rating and a price target of $8.75 (1 day ago). Here are 3rd party ratings for [TLYS](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 44% (111 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Groupon, Inc.]( Ticker: [GRPN]( Recent Price: $12.16 Average Analyst Price Target: $13.00 (6.91%) Market Cap: $387.34M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 9,540 $107,802 2 Days Ago Interim CEO, Director, >10% Owner Informative Buy Options Exercised and fully kept 1,528,586 $17,273,022 3 Days Ago Recent Analyst Action: Eric Sheridan, analyst at Goldman Sachs, reiterates coverage on [Groupon, Inc. (GRPN)]( in the Communication Services sector with a Sell rating and a price target of $7.5 (6 days ago). Here are 3rd party ratings for [GRPN](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 45% (113 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?]( little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming. [See what this potential vanadium hotspot could mean to investors.]( --------------------------------------------------------------- [Prothena Corporation plc]( Ticker: [PRTA]( Recent Price: $32.62 Average Analyst Price Target: $76.75 (135.29%) Market Cap: $1.75B Role Transaction Description No. of Shares Amount Date CAO Informative Buy Non Open Market Buy 5,000 $67,650 2 Days Ago Recent Analyst Action: Brian Abrahams, analyst at RBC Capital, reiterates coverage on [Prothena Corporation plc (PRTA)]( in the Healthcare sector with a Hold rating and a price target of $36 (9 hours ago). Here are 3rd party ratings for [PRTA](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 37% (94 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Inspire Medical Systems, Inc.]( Ticker: [INSP]( Recent Price: $214.93 Average Analyst Price Target: $230.50 (7.24%) Market Cap: $6.35B Role Transaction Description No. of Shares Amount Date CMO Informative Buy Non Open Market Buy 100 $15,350 2 Days Ago Recent Analyst Action: Michael Sarcone, analyst at Jefferies, reiterates coverage on [Inspire Medical Systems, Inc. (INSP)]( in the Healthcare sector with a Buy rating and a price target of $245 (6 days ago). Here are 3rd party ratings for [INSP](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 31% (78 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Is This The Most Overlooked Gold Investment Strategy of 2024?]( is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks. [Read this stunning report on a little-known gold royalty investment strategy]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software